Introduction {#s0005}
============

Gastric cancer (GC), one of the most common malignant tumors in the digestive tract, is the second most frequent cause of mortality worldwide [@bb0005]. Over the past couple of decades, although advances have been seen in surgical techniques and adjuvant chemotherapy, the prognosis of patients with GC still remains unsatisfactory [@bb0010]. Therefore, it is of important significance to identify promising prognostic factors to select patients for tailor treatment.

It is now increasingly recognized that the systemic inflammatory response plays an important role in carcinogenesis and tumor progression [@bb0015; @bb0020; @bb0025]. A number of studies have demonstrated that the systemic inflammatory response is associated with a poor prognosis in various types of cancer. Several common inflammation-based prognostic scores, including the Glasgow Prognostic Score (GPS), modified Glasgow prognostic score (mGPS), high-sensitivity modified Glasgow prognostic score (HS-mGPS), neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), have been reported to have prognostic significance in many types of cancer [@bb0030; @bb0035; @bb0040; @bb0045; @bb0050; @bb0055; @bb0060]. Recently, a new prognostic index, preoperative C-reactive protein/albumin (CRP/Alb) ratio, has also been reported as an independent prognostic marker in hepatocellular carcinoma [@bb0065]. However, compared with other established inflammation-based prognostic scores, the prognostic value of the CRP/Alb ratio in patients with GC is still unclear.

In this study, we performed a large-scale retrospective cohort analysis to investigate the prognostic value of the preoperative CRP/Alb ratio. We also compared it with several other markers of the systemic inflammatory response in patients undergoing curative resection for GC.

Material and Methods {#s0010}
====================

A total of 455 consecutive GC patients who received D2 gastrectomy with R0 resection at Cancer Center of Sun Yat-sen University between January 2005 and December 2010 were enrolled. D2 lymphadenectomy was performed following the Japanese Research Society for Gastric Cancer guidelines [@bb0070]. All patients were histologically confirmed as having stage I to III adenocarcinoma of the stomach depending on postoperative histological specimen. Our study complied with the standards of the Declaration of Helsinki and was approved by the Sun Yat-sen University Cancer Center research ethics committee. Every patient provided written informed consent before inclusion.

Data regarding potential prognostic factors were gathered, including age, sex, preoperative laboratory measurements, postoperative tumor characteristic, and survival times. Blood samples were obtained within 1 week before surgery to measure the neutrophil, lymphocyte, and platelet counts; Alb; and CRP. Tumor was staged according to the seventh edition of the American Joint Committee on Cancer tumor-nodes-metastasis (TNM) staging [@bb0075]. Patients were excluded if they had infection or inflammatory disease for nearly 1 month, immunity disease, and absent data regarding potential prognostic factors. Moreover, patients who received neoadjuvant chemotherapy or radiotherapy were excluded from the study. Patients were followed up carefully after surgery at 6- to 12-month intervals. A dynamic computed tomogram and a gastroscope examination were performed every 6 months. The last follow-up date was April 30, 2014. Overall survival (OS) was calculated from the date of surgery to the date of death or last follow-up.

Based on previous studies, preoperative body weight loss was defined as "no, or limited" (≤ 10%) or "severe" (\> 10%), and body mass index (BMI) was defined according to the following categories: \< 18.5 kg/m^2^, ≥ 18.5 to \< 23 kg/m^2^, ≥ 23 to \< 25.0 kg/m^2^, or ≥ 25.0 kg/m^2^ [@bb0080; @bb0085]. The NLR and PLR were defined as the absolute neutrophil count and platelet count divided by the absolute lymphocyte count [@bb0090]. The SII was calculated as follows: SII = *P* × *N*/*L*, where *P*, *N*, and *L* were the preoperative absolute platelet, neutrophil, and lymphocyte counts, respectively [@bb0045]. The GPS was calculated by CRP and Alb using standard thresholds (\> 10 mg/l for CRP and \< 35 g/l for Alb). Patients with both a CRP level \> 10 mg/l and an Alb level \< 35 g/l were categorized as having a score of 2. Patients with only one of these abnormalities were categorized as having a score of 1. Patients with neither of these abnormalities were categorized as having a score of 0 [@bb0095]. The mGPS was determined as previously described [@bb0060]. Patients with an elevated CRP level (\> 0.5 mg/dl) and hypoalbuminemia (\< 3.8 g/dl) were assigned an mGPS of 2, those with only one abnormality were assigned an mGPS of 1, and those with neither of these abnormalities were assigned an mGPS of 0. The HS-mGPS was determined as follows: patients with an elevated CRP level (\> 0.3 mg/dl) and hypoalbuminemia (\< 3.5 mg/dl) were assigned an HS-mGPS of 2, those with an abnormality in the CRP level were assigned an HS-mGPS of 1, and those with neither abnormality were assigned an HS-mGPS of 0 [@bb0055]. The CRP/Alb ratio was defined as the serum CRP level divided by the serum Alb level [@bb0100].

Statistical Analysis {#s0030}
====================

Descriptive statistics of patient characteristics were presented as mean and 95% confidence intervals (CIs). Comparisons between groups were performed using the *χ*^2^ test for categorical variables. If continuous variable was proven for the assumption of linearity in the logit, the variable was categorized by generating receiver operating characteristics (ROC) curve to identify the optimal cutoff value. Survival analysis and curves were performed according to the Kaplan-Meier method and compared by the log-rank test. A Cox proportional-hazard model for multivariable analysis was applied for variables that proved to be significant in the univariate analysis. If variables were significantly associated with other variables, they were excluded from the final multivariable analysis. Multivariate *P* values were used to characterize the independence and significance of these factors. The discriminatory ability of the factors to predict OS was assessed using the area under the curve (AUC).

Statistical analyses were performed using IBM SPSS 19.0 software (IBM Corporation, Armonk, NY). Differences at *P* \< .05 were considered to be significant in all statistical analyses.

Results {#s0015}
=======

The clinicopathological characteristics of 455 GC patients and their association with OS were summarized in [Table 1](#t0005){ref-type="table"}. The median age of the patients was 59 years (range, 19-86). Overall, 314 (69%) cases were males and 141 (31%) were females. The median follow-up period was 25 months (range, 1-76). There were 268 (58.9%) cases confirmed dead, and 187 (41.1%) were alive at last follow-up.

Based on previous studies, the accepted optimal cutoff value was determined for some variables, including preoperative body weight loss, BMI, neutrophil, lymphocyte, and platelet counts [@bb0080; @bb0085; @bb0105; @bb0110]. Besides the variables, ROC curve analysis was used to determine the optimal cutoff value for others. All the optimal cutoff values for variables were shown in [Table 1](#t0005){ref-type="table"}. The optimal cutoff value for the CRP/Alb ratio was 0.025 for the OS. The sensitivity and specificity were 76.8% and 48.1%, respectively. According to the cutoff level, patients were divided into two groups (≤ 0.025, *n* = 153; \> 0.025, *n* = 402). The 1-, 3-, and 5-year OS rates in patients with a CRP/Alb ratio ≤ 0.025 were 88.3%, 60.7%, and 54.5%, respectively. The survival rates were significantly higher than those in patients with a CRP/Alb ratio \> 0.025, which were 76.9%, 32.6%, and 26.9%, respectively (*P* \< .001; [Figure 1](#f0005){ref-type="fig"}*A*). In addition, when stratified by TNM stage, the prognostic significance of CRP/Alb ratio was still maintained in stage I to III (*P* = .009, *P* = .020, and *P* \< .001, respectively; [Figure 1](#f0005){ref-type="fig"}, *B*--*D*). A low CRP/Alb ratio was associated with longer median OS in stage I (72.0 vs 59.6 months), stage II (62.9 vs 47.9 months), and stage III (38.6 vs 26.4 months), respectively.

The relationship between the CRP/Alb ratio and clinicopathologic characteristics in GC patients was shown in [Table 3](#t0015){ref-type="table"}. Patients with an elevated CRP/Alb ratio were more likely found in males (*P* = .005) and were associated with age ≥ 60 years (*P* \< .001), higher neutrophil counts (*P* = .040), higher platelet counts (*P* = .001), elevated NLR (*P* \< .001), elevated PLR (*P* \< .001), elevated SII (*P* \< .001), higher GPS score (*P* \< .001), higher mGPS score (*P* \< .001), higher HS-mGPS score (*P* \< .001), tumor location (upper third) (*P* = .013), larger tumor size (*P* \< .001), elevated metastatic lymph node ratio (*P* = .005), and higher TNM stage (*P* \< .001).

The results of the univariate and multivariate analysis were shown in [Table 2](#t0010){ref-type="table"}. After excluding the related variables, the significant variables (age, tumor location, metastatic lymph node ratio, tumor size, TNM stage, NLR, PLR, SII, GPS, and CRP/Alb ratio) were tested in the multivariate analysis. The multivariate analysis indicated that the age \[hazard ratio (HR): 1.447; 95% CI: 1.130-1.853; *P* = .003\], preoperative body weight loss (HR: 1.324; 95% CI: 1.116-1.571; *P* = .001), CRP/Alb ratio (HR: 1.626; 95% CI: 1.191-2.219; *P* = .002), tumor location (HR: 0.824; 95% CI: 0.713-0.951; *P* = .008), metastatic lymph node ratio (HR: 2.511; 95% CI: 1.715-3.676; *P* \< .001), and seventh TNM stage (American Joint Committee on Cancer) (HR: 1.608; 95% CI: 1.138-2.273; *P* = .007) were independent prognostic factors for OS. When GPS was replaced by mGPS and HS-mGPS, respectively, the results of multivariate analysis did not change significantly ([Supplement Table 1](#ec0005){ref-type="supplementary-material"}).

As CRP/Alb ratio was significantly associated with other variables (age, tumor location, metastatic lymph node ratio, and seventh TNM stage), subgroup analyses were further performed to evaluate the prognostic value of CRP/Alb ratio more comprehensively. Of note, the prognostic significance was still maintained when stratified by age (\< 60: *P* \< .001; ≥ 60: *P* \< .001), tumor location (upper third: *P* = .001; middle third: *P* = .004; lower third: *P* = .007), and metastatic lymph node ratio (\< 0.17: *P* \< .001; ≥ 0.17: *P* \< .001).

Considering correlations among the markers of the systemic inflammatory response, we constructed ROC curves to further assess their discrimination ability ([Figure 2](#f0010){ref-type="fig"}). The discrimination ability of the CRP/Alb ratio, as assessed by AUC, was 0.625 (95% CI: 0.572-0.678; *P* \< .001), which was higher than that of other markers ([Table 4](#t0020){ref-type="table"}).

Discussion {#s0020}
==========

It is well known that the systemic inflammatory response plays an important role in carcinogenesis and tumor progression [@bb0115; @bb0120]. With proinflammatory cytokines releasing and the formation of an inflammatory microenvironment, inflammatory cells are powerful tumor promoters [@bb0125; @bb0130]. Inflammatory responses should also be thought of as antitumor, but cancer patients are often defective in inflammatory responses. To date, although the prognostic value of common inflammation-based prognostic scores, including the GPS, mGPS, HS-mGPS, NLR, PLR, SII, and CRP/Alb ratio, has been given great concern, the mechanisms underlying the relationship between inflammation and cancer survival have not been elucidated completely. It may be associated with malnutrition, immune dysfunction, upregulation of growth factors, angiogenesis, etc. [@bb0135; @bb0140]. In recent years, studies have demonstrated that several important inflammation-based prognostic scores are associated with various cancer survival outcomes [@bb0030; @bb0035; @bb0040; @bb0045; @bb0050].

Serum CRP, an acute-phase protein, is produced in hepatocytes, predominantly under the control of IL-6. It was shown to be very sensitive prognosis indicator of inflammation in a variety of primary malignancies, including GC [@bb0145; @bb0150; @bb0155]. On the other hand, low serum Alb levels, as a state of malnutrition, have also been considered to be associated with various cancer survival outcomes, for example, gastrointestinal, colorectal, lung, and ovarian cancer [@bb0160; @bb0165; @bb0170; @bb0175]. Furthermore, we can speculate that CRP/Alb ratio, which is based on both elevated serum CRP concentrations and hypoalbuminemia, may enable a better appreciation of the outcome of the malignancy. In fact, Akiyoshi et al. have proved that the CRP/Alb ratio is an independent prognostic marker in hepatocellular carcinoma [@bb0065].

Currently, we first investigate the prognostic significance of these markers in patients with GC. Of the inflammation-based prognostic scores, only the CRP/Alb ratio was significantly associated with OS and had prognostic value independent of TNM stage. More importantly, we found that its prognostic significance was substantially stable in stage I to III patients undergoing curative resection for GC. In hepatocellular carcinoma, Akiyoshi et al. also found that an elevated CRP/Alb ratio was associated with a higher Cancer of the Liver Italian Program score, Barcelona Clinic Liver Cancer stage, and Child-Pugh grade. The novel inflammation-based prognostic score had comparable prognostic ability to other inflammation-based prognostic scores. They demonstrated that an elevated CRP/Alb ratio was significantly parallel to tumor progression. Obviously, their conclusion was consistent with our study [@bb0065]. Moreover, we further explored the association between CRP/Alb ratio and nutritional status. We found that it was not significantly associated with preoperative body weight loss and BMI, although CRP/Alb ratio reflected not only inflammation but also nutritional status of cancer patients. The data suggested, in terms of CRP/Alb ratio, that systemic inflammatory response exerted more potent prognostic effect than nutritional status. In addition, a study from Crumley et al. demonstrated that the relation between hypoalbuminemia and poor outcome was secondary to that of the systemic inflammatory response, which might also explain part of the reason [@bb0160].

In our study, the multivariate analysis revealed that only the CRP/Alb ratio, rather than other inflammation-based prognostic scores, was independently associated with OS. Considering that preoperative systemic inflammation might be associated with postoperative infection that led to poor clinical outcome, we rechecked follow-up data to further explore whether CRP/Alb ratio adversely affected postoperative short-term survival. We found that 25 cases died within half a year after surgery and that none of them died of postoperative infection. Therefore, CRP/Alb ratio was considered ideal to evaluate prognosis in GC. More importantly, we found that the prognostic significance, regardless of TNM stage, was substantially stable. This may be useful for postoperative evaluation of recurrence after curative surgery, especially in early-stage patients in whom tumor relapse is difficult to predict.

To further evaluate the discrimination ability of the inflammation-based prognostic scores, ROC curves were performed to compare the AUC value. The CRP/Alb ratio had a higher AUC value than other markers (0.625; *P* \< .001). A study from Xu et al. indicated that the GPS was superior to the NLR and PLR and was associated with OS in patients undergoing potential curative resection for stage III GC [@bb0180]. Takeno et al. revealed that the HS-mGPS was a superior prognostic predictor compared with the mGPS in patients with GC [@bb0055]. Hu et al. also showed that the SII could be a more objective index than the NLR and PLR in hepatocellular carcinoma [@bb0045]. As far as we know, this is the first to include the SII in GC. Our study proved that the CRP/Alb ratio, in terms of its prognostic ability, was superior to other inflammation-based prognostic scores, including the GPS, mGPS, HS-mGPS, NLR, PLR, and SII. Although the GPS, mGPS, and HS-mGPS use the same variables to estimate the scores, they may have the potential for underestimation (a lower CRP level) or overestimation (a lower Alb level) in patients with GC. However, the CRP/Alb ratio reduces these potential by using the ratio of the CRP and Alb, which may be superior to them in GC.

It is worth noting that our findings may have important value in the therapy of GC. With an elevated CRP/Alb ratio, early-stage patients may need closer follow-up, and local advanced patients may require more aggressive adjuvant chemotherapy or additional active therapy. In addition, patients with an elevated CRP/Alb ratio may benefit from anti-inflammatory therapy or nutritional support [@bb0185; @bb0190; @bb0195]. Future studies, especially prospective multicenter clinical trials, are warranted as validation studies.

We acknowledge several potential limitations in present study. First, it was a retrospective, single-institution, and small-sample-size study. However, the surgical procedures (R0 resection plus D2 lymphadenectomy), laboratory examinations, and follow-up were uniform throughout the entire study period. Second, different postoperative therapy might induce confounding. Third, we lacked the data of disease-free survival, although OS was the standard indicator for cancer prognosis study.

Conclusions {#s0025}
===========

To our knowledge, we first demonstrate that preoperative CRP/Alb ratio is an independent prognostic marker in patients after curative resection for GC. Moreover, its prognostic ability is superior to other inflammation-based prognostic scores. Due to its simplicity, cheapness, and availability, it is of important significance to help clinicians identify the high-risk patients and enable postoperative targeted rational therapy.

The following are the supplementary data related to this article.Supplement Table 1Multivariate Analyses of OS
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###### 

Clinical and Laboratory Characteristics of 455 GC Patients Associated with OS

                                   No. of Patients (%)   OS (Months) Mean (95% CI)   *P* Value[⁎](#tf0005){ref-type="table-fn"}
  -------------------------------- --------------------- --------------------------- --------------------------------------------
  Patient-related factors                                                            
   Sex                                                                               .895
   Male                            314 (69.0%)           39.8 (36.5-43.0)            
   Female                          141 (31.0%)           40.1 (35.1-45.0)            
   Age (years)                                                                       .002
   \< 60                           252 (55.4%)           43.9 (40.2-47.5)            
   ≥ 60                            203 (44.6%)           34.9 (31.0-38.8)            
   Preoperative body weight loss                                                     \< .001
   No                              220 (48.4%)           46.3 (42.3-50.3)            
   Limited                         170 (37.4%)           36.8 (32.6-40.9)            
   Severe                          65 (14.3%)            26.6 (20.8-32.5)            
   BMI (kg/m^2^)                                                                     .108
   \< 18.5                         71 (15.6%)            32.2 (26.0-38.5)            
   18.5 ≤ \< 23.0                  223 (49.0%)           41.2 (37.3-45.1)            
   23.0 ≤ \< 25.0                  90 (19.8%)            40.0 (33.7-46.0)            
   25.0 ≤                          71 (15.6%)            42.7 (36.1-49.4)            
   Neutrophils (× 10^9^/L)                                                           .002
   \< 7.5                          417 (91.6%)           41.1 (38.3-44.0)            
   ≥ 7.5                           38 (8.4%)             26.1 (19.1-33.1)            
   Lymphocytes (× 10^9^/L)                                                           .510
   \< 3                            431 (94.7%)           40.2 (37.4-43.0)            
   ≥ 3                             24 (5.3%)             34.1 (23.8-44.4)            
   Platelet (× 10^9^/L)                                                              .478
   \< 400                          416 (91.4%)           40.3 (37.4-43.1)            
   ≥ 400                           39 (8.6%)             35.3 (26.7-43.8)            
   CRP (mg/L)                                                                        .002
   ≤ 10                            388 (85.3%)           41.6 (38.6-44.6)            
   \> 10                           67 (14.7%)            29.8 (23.8-35.8)            
   Alb (g/L)                                                                         \< .001
   \< 35                           51 (11.2%)            24.2 (18.7-29.8)            
   ≥ 35                            404 (88.8%)           41.7 (38.9-44.6)            
   NLR                                                                               \< .001
   \< 2.3                          269 (59.1%)           44.6 (41.0-48.2)            
   ≥ 2.3                           186 (40.9%)           33.3 (29.4-37.2)            
   PLR                                                                               \< .001
   \< 180                          336 (73.8%)           42.8 (39.6-46.0)            
   ≥ 180                           119 (26.2%)           31.3 (26.6-35.9)            
   SII                                                                               .001
   \< 660                          302 (66.4%)           43.1 (39.7-46.5)            
   ≥ 660                           153 (33.6%)           33.5 (29.3-37.7)            
   GPS                                                                               \< .001
   0                               350 (76.9%)           43.6 (40.5-46.7)            
   1                               92 (20.2%)            26.8 (21.9-31.6)            
   2                               13 (2.9%)             29.9 (19.2-40.5)            
   mGPS                                                                              .001
   0                               274 (60.2%)           44.1 (40.6-47.7)            
   1                               145 (31.9%)           33.9 (29.5-38.4)            
   2                               36 (7.9%)             31.8 (22.9-40.7)            
   HS-mGPS                                                                           .006
   0                               295 (64.8%)           42.7 (39.3-46.1)            
   1                               135 (29.7%)           35.8 (31.0-40.7)            
   2                               25 (5.5%)             24.5 (17.5-31.5)            
   CRP/Alb ratio                                                                     \< .001
   \< 0.25                         153 (33.6%)           51.7 (47.0-56.3)            
   ≥ 0.25                          302 (66.4%)           34.2 (31.0-37.3)            
  Tumor-related factors                                                              
   Tumor location Upper third      178 (39.1%)           32.1 (28.3-36.0)            \< .001
   Middle third                    100 (22.0%)           38.8 (32.9-44.7)            
   Lower third                     177 (38.9%)           48.4 (44.0-52.8)            
   Tumor size (cm)                                                                   \< .001
   \< 3                            155 (34.1%)           49.3 (44.5-54.1)            
   ≥ 3                             300 (65.9%)           35.0 (31.9-38.2)            
   Metastatic lymph node ratio                                                       \< .001
   \< 0.17                         195 (42.9%)           56.6 (52.7-60.4)            
   ≥ 0.17                          260 (57.1%)           27.4 (24.5-30.2)            
   TNM stage                                                                         \< .001
   I                               60 (13.2%)            67.1 (61.6-72.5)            
   II                              95 (20.9%)            53.6 (47.9-59.3)            
   III                             300 (65.9%)           30.0 (27.1-32.9)            

Kaplan-Meier survival analysis.

###### 

Univariate and Multivariate Analyses of OS

                                   Univariate Analysis   Multivariate Analysis                         
  -------------------------------- --------------------- ----------------------- --------------------- ---------
  Patient-related factors                                                                              
   Sex                             0.983 (0.757-1.276)   .896                                          
   Male                                                                                                
   Female                                                                                              
   Age (years)                     1.461 (1.149-1.856)   .002                    1.447 (1.130-1.853)   .003
   \< 60                                                                                               
   ≥ 60                                                                                                
   Preoperative body weight loss   1.533 (1.301-1.806)   \< .001                 1.324 (1.116-1.571)   .001
   No                                                                                                  
   Limited                                                                                             
   Severe                                                                                              
   BMI (kg/m^2^)                   0.888 (0.777-1.016)   .083                                          
   \< 18.5                                                                                             
   18.5 ≤ \< 23.0                                                                                      
   23.0 ≤ \< 25.0                                                                                      
   25.0 ≤                                                                                              
   Neutrophils (× 10^9^/L)         1.826 (1.241-2.686)   .002                                          
   \< 7.5                                                                                              
   ≥ 7.5                                                                                               
   Lymphocytes (× 10^9^/L)         1.183 (0.713-1.960)   .515                                          
   \< 3                                                                                                
   ≥ 3                                                                                                 
   Platelet (× 10^9^/L)            1.165 (0.759-1.787)   .484                                          
   \< 400                                                                                              
   ≥ 400                                                                                               
   CRP (mg/L)                      1.632 (1.193-2.232)   .002                                          
   ≤ 10                                                                                                
   \> 10                                                                                               
   Alb (g/L)                       0.507 (0.362-0.710)   \< .001                                       
   \< 35                                                                                               
   ≥ 35                                                                                                
   NLR                             1.634 (1.285-2.078)   \< .001                 1.095 (0.797-1.503)   .576
   \< 2.3                                                                                              
   ≥ 2.3                                                                                               
   PLR                             1.588 (1.227-2.057)   \< .001                 1.204 (0.879-1.650)   .247
   \< 180                                                                                              
   ≥ 180                                                                                               
   SII                             1.493 (1.168-1.907)   .001                    1.036 (0.723-1.485)   .846
   \< 660                                                                                              
   ≥ 660                                                                                               
   GPS                             1.634 (1.324-2.015)   \< .001                 1.160 (0.910-1.478)   .230
   0                                                                                                   
   1                                                                                                   
   2                                                                                                   
   mGPS                            1.394 (1.166-1.668)   \< .001                                       
   0                                                                                                   
   1                                                                                                   
   2                                                                                                   
   HS-mGPS                         1.361 (1.119-1.654)   .002                                          
   0                                                                                                   
   1                                                                                                   
   2                                                                                                   
   CRP/Alb ratio                   2.225 (1.673-2.960)   \< .001                 1.626 (1.191-2.219)   .002
   \< 0.25                                                                                             
   ≥ 0.25                                                                                              
  Tumor-related factors                                                                                
   Tumor location                  0.706 (0.615-0.810)   \< .001                 0.824 (0.713-0.951)   .008
   Upper third                                                                                         
   Middle third                                                                                        
   Lower third                                                                                         
   Tumor size (cm)                 1.900 (1.440-2.507)   \< .001                 0.944 (0.698-1.277)   .710
   \< 3                                                                                                
   ≥ 3                                                                                                 
   Metastatic lymph node ratio     4.011 (3.021-5.325)   \< .001                 2.511 (1.715-3.676)   \< .001
   \< 0.17                                                                                             
   ≥ 0.17                                                                                              
   TNM stage                       2.979 (2.317-3.831)   \< .001                 1.608 (1.138-2.273)   .007
   I                                                                                                   
   II                                                                                                  
   III                                                                                                 

###### 

Relationship between the CRP/Alb Ratio and Clinicopathologic Characteristics

                                   CRP/Alb Ratio \< 0.25   CRP/Alb Ratio ≥ 0.25   *P* Value
  -------------------------------- ----------------------- ---------------------- -----------
  Patient-related factors                                                         
   Sex                                                                            .005
   Male                            93                      222                    
   Female                          60                      80                     
   Age (years)                                                                    \< .001
   \< 60                           103                     150                    
   ≥ 60                            50                      152                    
   Preoperative body weight loss                                                  .363
   No                              81                      139                    
   Limited                         53                      117                    
   Severe                          19                      46                     
   BMI (kg/m^2^)                                                                  .315
   \< 18.5                         19                      52                     
   18.5 ≤ \< 23.0                  81                      142                    
   23.0 ≤ \< 25.0                  33                      57                     
   25.0 ≤                          20                      51                     
   Neutrophils (× 10^9^/L)                                                        .040
   \< 7.5                          146                     271                    
   ≥ 7.5 × 10^9^/L                 7                       31                     
   Lymphocytes (× 10^9^/L)                                                        .688
   \< 3                            144                     287                    
   ≥ 3                             9                       15                     
   Platelet (× 10^9^/L)                                                           .001
   \< 400                          149                     267                    
   ≥ 400                           4                       35                     
   NLR                                                                            \< .001
   \< 2.3                          118                     151                    
   ≥ 2.3                           35                      151                    
   PLR                                                                            \< .001
   \< 180                          130                     206                    
   \< 180                          23                      96                     
   SII                                                                            \< .001
   \< 660                          121                     182                    
   \< 660                          32                      120                    
   GPS                                                                            \< .001
   0                               148                     201                    
   1                               4                       88                     
   2                               0                       13                     
   mGPS                                                                           \< .001
   0                               133                     141                    
   1                               20                      125                    
   2                               0                       36                     
   HS-mGPS                                                                        \< .001
   0                               153                     142                    
   1                               0                       135                    
   2                               0                       25                     
  Tumor-related factors                                                           
   Tumor location                                                                 .013
   Upper third                     48                      130                    
   Middle third                    32                      68                     
   Lower third                     73                      104                    
   Tumor size (cm)                                                                \< .001
   \< 3                            78                      78                     
   ≥ 3                             75                      224                    
   Metastatic lymph node ratio                                                    .005
   \< 0.17                         80                      115                    
   ≥ 0.17                          173                     187                    
   TNM stage                                                                      \< .001
   I                               34                      27                     
   II                              34                      60                     
   III                             85                      215                    

###### 

Comparison of the AUCs for the Seven Inflammation-Based Prognostic Scores

                  AUC     95% CI          *P* Value
  --------------- ------- --------------- -----------
  CRP/Alb ratio   0.625   (0.572-0.678)   \< .001
  NLR             0.594   (0.541-0.646)   .001
  PLR             0.564   (0.511-0.617)   .021
  SII             0.571   (0.518-0.624)   .010
  GPS             0.581   (0.528-0.633)   .003
  mGPS            0.576   (0.523-0.629)   .006
  HS-mGPS         0.543   (0.489-0.596)   .012

[^1]: Contributed equally to this work.
